1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Dermatitis Report is to understand the market and pipeline status of the drugs around the Dermatitis to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Dermatitis. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Dermatitis.
- A review of the marketed products under prescription for Dermatitis, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Dermatitis with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Dermatitis drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Dermatitis drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Dermatitis drugs.
- Coverage of Dermatitis Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Dermatitis key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Dermatitis.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Dermatitis.
- API intelligence over marketed drugs forDermatitisand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Dermatitis.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Dermatitis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Dermatitis
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Dermatitis
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Dermatitis
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Dermatitis Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Dermatitis Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Dermatitis Therapeutic Market, US, (Year), 2017
- Dermatitis Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Dermatitis Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Dermatitis Drugs, API Manufacturers, Europe by Country, 2017
- Dermatitis Drugs, API Manufacturers, India by State, 2017
- Dermatitis Drugs, API Manufacturers, China by Province, 2017
- Dermatitis Drugs, API Manufacturers by Geography 2017
- Dermatitis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Dermatitis Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Dermatitis, 2017
- Discontinued Drugs for Dermatitis, 2017


List of Figures

- Dermatitis Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Dermatitis Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Dermatitis Therapeutic Market, US, (Year), 2017
- Dermatitis Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Dermatitis Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Dermatitis Drugs, API Manufacturers, Europe by Country, 2017
- Dermatitis Drugs, API Manufacturers, India by State, 2017
- Dermatitis Drugs, API Manufacturers, China by Province, 2017
- Dermatitis Drugs, API Manufacturers by Geography 2017
- Dermatitis Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Dermatitis Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • November 2016
  • by Transparency Market Research

Global Scleroderma Diagnostics and Therapeutics Market: Overview Scleroderma, a very rare autoimmune disorder of the skin, is a term coined from the Greek words “sklerosis,” which means hardness, and ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Epiomic Epidemiology Series: Acne Vulgaris Forecast in 15 Major Markets 2016-2026

Epiomic Epidemiology Series: Acne Vulgaris Forecast in 15 Major Markets 2016-2026

  • $ 5112
  • Industry report
  • December 2016
  • by Black Swan Analysis Ltd132

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acne Vulgaris in 15 Major Markets Acne, or Acne Vulgaris (AV), is a chronic inflammatory disease of the pilosebaceous unit. Although ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.